Skip to content
  • Home
  • Resources
    • Azurity Code of Conduct
    • Azurity Solutions
    • E-Z Rx®
    • Patient Direct
    • Patient Support
    • News & Events
    • Compliance
    • Medical Information
    • Careers
  • Contact Us
Azurity Pharmaceuticals
  • Company
    • About Us
    • Management Team
    • Board of Directors
  • Products
    • Products
    • Cardiovascular
      • BiDil®
      • Edarbi®
      • Edarbyclor®
      • Epaned ®
      • Katerzia®
      • Qbrelis®
    • Central Nervous System
      • EPRONTIA™
      • Evekeo®
      • Evekeo ODT®
      • FLEQSUVY™
      • Horizant®
      • Zenzedi®
      • ZONISADE™
    • Endocrinology
      • ADTHYZA™
    • Gastrointestinal
      • KONVOMEP™
    • Institutional / Orphan
      • FIRVANQ® (Anti-Infective)
      • Gliadel® Wafer (Oncology, Implantable Device)
      • Nymalize®
      • Sotylize®
      • Triptodur®
      • Xatmep® (Oncology, Rheumatology)
    • Certain products listed may be owned by a subsidiary of Azurity Pharmaceuticals.
  • Pipeline
  • Compounding Kits
    • Compounding Kits
    • FIRST® – Lansoprazole
    • FIRST® – BLM Mouthwash
    • FIRST® – Metronidazole
    • FIRST® – Progesterone
Select Page

NovaQuest Capital Management Acquires CutisPharma, Inc.

by GOT | Mar 26, 2018 | CutisPharma Press Releases, News

NovaQuest Capital Management Acquires CutisPharma, Inc. WILMINGTON, Mass. (Mar. 26, 2018) – CutisPharma, Inc. (“CutisPharma”), a specialty pharmaceutical company that for two decades has been the industry leader in providing innovative solutions to pharmacists, with...

Recent Posts

  • AZURITY PHARMACEUTICALS, INC. ANNOUNCES U.S. AVAILABILITY OF ZONISADE™ (zonisamide oral suspension)
  • AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension)
  • AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF ZONISADE™ (zonisamide oral suspension)
  • Azurity Pharmaceuticals Announces Richard Blackburn as New CEO
  • AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF FLEQSUVY™

Recent Comments

    Archives

    • October 2022
    • September 2022
    • July 2022
    • February 2022
    • November 2021
    • September 2021
    • August 2021
    • February 2021
    • August 2020
    • July 2019
    • June 2019
    • April 2018
    • March 2018
    • January 2018

    Categories

    • CutisPharma Press Releases
    • Legacy Arbor Archives
    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Home

    Pipeline

    Contact Us

    Company

    • About Us
    • Management Team
    • Board of Directors
    • Follow
    • Follow

    Products

    • ADTHYZA™
    • BiDil®
    • Edarbi®
    • Edarbyclor®
    • Epaned®
    • EPRONTIA™
    • Evekeo®
    • Evekeo ODT®
    • Firvanq®
    • FLEQSUVY™
    • Gliadel® Wafer
    • Horizant®
    • Katerzia®
    • KONVOMEP™
    • Nymalize®
    • Qbrelis®
    • Sotylize®
    • Triptodur®
    • Xatmep®
    • Zenzedi®
    • Zonisade™

    Compounding Kits

    • FIRST® – Lansoprazole
    • FIRST® – BLM Mouthwash
    • FIRST® – Metronidazole
    • FIRST® – Progesterone

    Resources

    • Azurity Code of Conduct
    • Azurity Solutions
    • E-Z Rx®
    • Patient Direct
    • Patient Assistance
    • News & Events
    • Compliance
    • Medical Information
    • Careers
    • Terms of Use
    • Privacy Policy and Cookie Notice
    • Web Accessibility Policy

    Azurity Pharmaceuticals, Inc. was formerly known as CutisPharma, Inc., parent company of Silvergate Pharmaceuticals, Inc. Product labeling, packaging, and imagery are for representation purposes only and shall constitute the property of Azurity and all applicable affiliates.

    The Information contained herein, including product information, is intended only for residents of the United States.

    © 2019 – 2023 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners. PP-FKS-US-0084
    AZ_Logo_White
    ADA Site Compliance-Accessibility Policy